Brief: Cullinan Therapeutics Licenses Rights to Velinotamig
04/06/2025 21:11
June 4 (Reuters) - Cullinan Therapeutics Inc CGEM.O: CULLINAN THERAPEUTICS LICENSES RIGHTS TO VELINOTAMIG, A CLINICAL-STAGE BCMA-DIRECTED BISPECIFIC T CELL ENGAGER, FROM GENRIX BIO FOR DEVELOPMENT IN AUTOIMMUNE DISEASES CULLINAN THERAPEUTICS INC - TO PAY $20 MILLION UPFRONT LICENSE FEE TO GENRIX BIO CULLINAN THERAPEUTICS INC - GENRIX ELIGIBLE FOR UP TO $292 MILLION IN MILESTONES CULLINAN THERAPEUTICS INC - EXPECTS CASH RESOURCES TO LAST INTO 2028 CULLINAN THERAPEUTICS : GENRIX TO RECEIVE UP TO AN ADDITIONAL $400M IN SALES-BASED MILESTONES Source text: ID:nGNXc1sZxw Further company coverage: CGEM.O ((Reuters.Briefs@thomsonreuters.com;))